[{"address1": "4-6 Bligh Street", "address2": "Suite 12.01, Level 12", "city": "Sydney", "state": "NSW", "zip": "2000", "country": "Australia", "phone": "61 2 9423 0881", "fax": "61 2 9423 0881", "website": "https://www.imugene.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy CHECKvacc in phase 1 clinical trial for triple negative breast cancer; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic and advanced gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. The company has a research collaboration with NeoImmuneTech to enhance cancer treatments. Imugene Limited is based in Sydney, Australia.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD", "age": 68, "title": "Executive Chairman", "yearBorn": 1956, "fiscalYear": 2024, "totalPay": 202680, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leslie  Chong", "title": "CEO, MD & Executive Director", "fiscalYear": 2024, "totalPay": 871735, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD", "age": 58, "title": "CFO & Company Secretary", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 327646, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Bradley  Glover M.B.A., Ph.D.", "age": 55, "title": "Chief Operating Officer", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 550822, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Joseph Paul Woodard Jr., M.D.", "title": "Chief Medical Officer", "fiscalYear": 2024, "totalPay": 631089, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ursula  McCurry", "title": "Chief Clinical Operations Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John  Byon M.D.", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 1, "overallRisk": 10, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 4, "previousClose": 0.023, "open": 0.024, "dayLow": 0.023, "dayHigh": 0.024, "regularMarketPreviousClose": 0.023, "regularMarketOpen": 0.024, "regularMarketDayLow": 0.023, "regularMarketDayHigh": 0.024, "beta": 3.34, "volume": 169300, "regularMarketVolume": 169300, "averageVolume": 162435, "averageVolume10days": 124766, "averageDailyVolume10Day": 124766, "bid": 0.0245, "ask": 0.0255, "marketCap": 183440832, "fiftyTwoWeekLow": 0.0044, "fiftyTwoWeekHigh": 0.105, "priceToSalesTrailing12Months": 36.909393, "fiftyDayAverage": 0.0258224, "twoHundredDayAverage": 0.03543435, "currency": "USD", "enterpriseValue": 86412952, "floatShares": 6179645782, "sharesOutstanding": 7564570112, "heldPercentInsiders": 0.14341, "heldPercentInstitutions": 0.06637, "impliedSharesOutstanding": 7710230016, "bookValue": 0.016, "priceToBook": 1.515625, "lastFiscalYearEnd": 1719705600, "nextFiscalYearEnd": 1751241600, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -149680544, "trailingEps": -0.01, "enterpriseToRevenue": 17.387, "enterpriseToEbitda": -0.629, "52WeekChange": -0.6655172, "SandP52WeekChange": 0.21142256, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "IUGNF", "underlyingSymbol": "IUGNF", "shortName": "Imugene, Ltd.", "longName": "Imugene Limited", "firstTradeDateEpochUtc": 1562333400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "1cadf534-efa9-3439-bad0-57391ecaca1b", "messageBoardId": "finmb_11113368", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.02425, "recommendationKey": "none", "totalCash": 93107536, "totalCashPerShare": 0.013, "ebitda": -137446624, "totalDebt": 1281263, "quickRatio": 3.609, "currentRatio": 3.858, "totalRevenue": 4970031, "debtToEquity": 1.083, "revenuePerShare": 0.001, "returnOnAssets": -0.50875, "returnOnEquity": -0.97233003, "grossProfits": 4970031, "freeCashflow": -69348912, "operatingCashflow": -101726144, "grossMargins": 1.0, "operatingMargins": 22.856941, "financialCurrency": "AUD", "trailingPegRatio": null, "__fetch_time": "2025-02-08"}]